VivaSon Group has sold a minority stake to Korian

Korian has acquired a minority stake in VivaSon Group.

Korian is a French company specialized in nursing home care for the elderly. Listed on Euronext Paris, Korian has nursing homes in France, Germany, Belgium, Italy, Spain and the Netherlands.

Founded in 2006, VivaSon is a family group dedicated to the distribution of auditory prostheses through a network of approximately 30 points of sale in France. The company had a turnover of US$18 million in 2020.

Oaklins’ team in France acted as buy-side advisor in this transaction.

SERVICIO

M&A buy-side

PARTES

Contáctese con el equipo de la transacción

Arnaud Dubois

Asesor Senior

Lyon, Francia
Oaklins France

Ver perfil Contáctenos

Transacciones relacionadas

MEDIK Hospital Design Group has been acquired by STERIS

Servicios de Construcción e Ingeniería | Salud

MEDIK Hospital Design Group has been acquired by STERIS

The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.

bioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG

Salud

bioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG

Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.

Banook, backed by Motion Equity, has acquired Fluidda

Salud | TMT

Banook, backed by Motion Equity, has acquired Fluidda

Banook Group has acquired Fluidda NV, marking a strategic expansion into advanced in-silico trials and respiratory disease modeling. Combining Banook’s expertise in cardiac safety and clinical data services with Fluidda’s AI-driven respiratory analytics creates a powerful, integrated platform. This deal strengthens Banook’s position in the contract research organization (CRO) sector, offering pharmaceutical clients broader, technology-enabled solutions to drive drug development and reduce costs.